Compagnie Lombard Odier SCmA’s Clovis Oncology, Inc. CLVS Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,000	Closed	-$44K	–	857
2016 Q4	$44K	Sell	1,000 -1,500	-60%	-$52.8K	﹤0.01%	621
2016 Q3	$90K	Buy	+2,500	New	+$53.6K	﹤0.01%	593
2015 Q2	–	Sell	-1,500	Closed	-$111K	–	952
2015 Q1	$111K	Buy	+1,500	New	+$106K	﹤0.01%	635

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Compagnie Lombard Odier SCmA's CLVS Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Clovis Oncology, Inc. (CLVS) in Q1 2017, closing a stake of 1,000 shares — an estimated $44K sold.

Compagnie Lombard Odier SCmA first reported a position in CLVS in Q1 2015 and held it in 3 quarters. The position peaked at $111K in Q1 2015. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2017.

Compagnie Lombard Odier SCmA reported no remaining Clovis Oncology, Inc. position as of Q1 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 1,000 Clovis Oncology, Inc. shares in Q1 2017, an estimated $44K.
Compagnie Lombard Odier SCmA first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 3 quarters.
Compagnie Lombard Odier SCmA's Clovis Oncology, Inc. position peaked at $111K in Q1 2015.
229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.